Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298408 · ClinicalTrials.gov registry record · Phase 1
Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
A Phase 1 study, sponsored by Florida A&M University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07298408 is a Phase 1 study that is actively recruiting participants, run by Florida A&M University. The registered enrollment target is 20 participants.
The verdict
NCT07298408, a Phase 1 study, is actively recruiting participants, sponsored by Florida A&M University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).
Interventions
- DRUG Cannabidiol (CBD) oral solution
- DRUG Full-Spectrum CBD hemp extract oral solution
- DRUG Placebo in MCT oil oral solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04-02 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298408
The ClinicalTrials.gov registry entry for NCT07298408 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida A&M University, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cannabidiol (CBD) oral solution is the first listed.
NCT07298408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07298408 about?
NCT07298408 is a clinical study titled "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study". The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associate...
What is the current status of trial NCT07298408?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04-02. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07298408?
The interventions under investigation include: Cannabidiol (CBD) oral solution (DRUG), Full-Spectrum CBD hemp extract oral solution (DRUG), Placebo in MCT oil oral solution (DRUG).
Who is sponsoring clinical trial NCT07298408?
This trial is sponsored by Florida A&M University, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.